How should lactic acidosis be managed in a patient with MASH (metabolic dysfunction-associated steatohepatitis) cirrhosis?

Management of Lactic Acidosis in MASH Cirrhosis

Metformin must be immediately discontinued in any patient with MASH cirrhosis who develops lactic acidosis, and should never be used in decompensated cirrhosis due to the high risk of this life-threatening complication 1.

Immediate Management Priorities

When lactic acidosis occurs in a MASH cirrhosis patient, the clinical approach must focus on:

1. Discontinue Metformin Immediately

The 2024 EASL-EASD-EASO guidelines explicitly state that metformin should not be used in adults with decompensated cirrhosis, especially when there is concomitant renal impairment, specifically because of lactic acidosis risk 1. Even in compensated cirrhosis, metformin can only be used if renal function is preserved 1.

2. Assess Cirrhosis Severity and Organ Function

Determine if the patient has:

• Compensated vs. decompensated cirrhosis - presence of ascites, encephalopathy, variceal bleeding, or jaundice indicates decompensation
• Renal function - creatinine levels are critical (≥2.0 mg/dL indicates renal failure and ACLF grade Ia) 2
• Other organ failures using the CLIF-SOFA score system 2

3. Evaluate for ACLF (Acute-on-Chronic Liver Failure)

Lactic acidosis in cirrhosis may signal ACLF, which carries extremely high mortality:

• ACLF Grade II (two organ failures): 32% 28-day mortality
• ACLF Grade III (three or more organ failures): 78% 28-day mortality 2

The CLIF-C Organ Failure score should be calculated to assess kidney (creatinine), liver (bilirubin), brain (hepatic encephalopathy), coagulation (INR), circulation (MAP), and lung function 2.

Critical Clinical Pitfalls

Common mistake: Continuing metformin in compensated cirrhosis patients who develop acute decompensation or renal impairment. The guidelines are clear that metformin contraindication extends beyond baseline decompensation to include any acute deterioration in renal function 1.

Renal threshold: Even creatinine 1.5-1.9 mg/dL combined with other organ dysfunction qualifies as ACLF grade Ib 2, and metformin should have been stopped well before this point.

Supportive Management

Since there is no specific treatment for ACLF 2, management focuses on:

• Organ support - addressing renal failure, hemodynamic instability, and other failing organs
• Identifying precipitants - infections, gastrointestinal bleeding, hepatotoxins, or other acute insults 2
• Intensive monitoring - these patients require close observation given the high short-term mortality

Alternative Diabetes Management in Cirrhosis

For future diabetes management in MASH cirrhosis patients:

Compensated cirrhosis (Child-Pugh A):

• GLP-1 receptor agonists can be used 1
• SGLT2 inhibitors can be used in Child-Pugh A and B 1

Decompensated cirrhosis:

• Insulin is the preferred agent 3
• Avoid sulfonylureas due to hypoglycemia risk 1
• Never use metformin 1

The key distinction is that metformin's lactic acidosis risk makes it uniquely dangerous in this population, whereas other glucose-lowering agents have different safety profiles that may permit their use depending on cirrhosis severity.